
............................
+ History
............................
Investment Approach
& Strategy
............................
|
 History
New Leaf Venture Partners was formed in 2005, when the healthcare team
spun out from the Sprout Group, the venture capital affiliate of Credit
Suisse. The NLV team has been built over more than 15 years and has
managed the health care technology portfolios in five Sprout funds as
well as in two of its own NLV funds:
New Leaf Ventures I, L.P., a $310 million fund that closed in 2005
New Leaf Ventures II, L.P., a $450 million fund that closed in late 2007 and began its new investment cycle in 2008
The NLV team has invested more than $1.3 billion together in over 100
healthcare technology companies. The team’s investments have spanned a
range of opportunities, including investments in start ups, private
financings, PIPEs, structured financings, and small buyouts. Some
representative investments include Adeza Biomedical (Cytyc)
*, Aradigm Corporation, Aspreva Pharmaceuticals (Galenica
Group), Cephalon, Cerexa (Forest Laboratories),
CombiChem (DuPont), Epicor Medical (St. Jude),
ePocrates, Ilypsa (Amgen), NxStage Medical,
Oriel Therapeutics (Novartis-Sandoz Div.), Pathology
Partners (Caris Ltd), Phase Forward (Oracle),
Sapient Health Networks (WebMD), Visiogen
(Abbott), and VNUS Medical Technologies (Covidien). The
team also led recapitalizations of established companies such as
Sirna Therapeutics (Merck) and ISTA Pharmaceuticals.
Both New Leaf Ventures I and New Leaf Ventures II are capitalized by
commitments from highly respected limited partners, many of whom have
invested with the New Leaf team over multiple funds. These limited
partners include a mix of large corporate and public sector pension
funds, funds of funds, endowments, and other private investors.
* Company in parentheses and italics denotes acquiring company |